Age 0 3 0 3 B-age
> 4 5 4 5 O
/= 5 7 5 7 O
60 8 10 8 10 B-lower_bound
years 11 16 11 16 I-lower_bound

Histological 0 12 17 29 O
confirmation 13 25 30 42 O
of 26 28 43 45 O
relapsed 29 37 46 54 O
or 38 40 55 57 O
refractory 41 51 58 68 O
AML 52 55 69 72 B-cancer
after 56 61 73 78 O
prior 62 67 79 84 B-treatment
anti 68 72 85 89 I-treatment
- 72 73 89 90 I-treatment
leukemic 73 81 90 98 I-treatment
therapy 82 89 99 106 I-treatment
by 90 92 107 109 O
WHO 93 96 110 113 O
Classification 97 111 114 128 O

History 0 7 129 136 O
of 8 10 137 139 O
symptomatic 11 22 140 151 B-chronic_disease
Clostridium 23 34 152 163 I-chronic_disease
difficile 35 44 164 173 I-chronic_disease
infection 45 54 174 183 I-chronic_disease
within 55 61 184 190 O
1 62 63 191 192 B-upper_bound
month 64 69 193 198 I-upper_bound
prior 70 75 199 204 I-upper_bound
to 76 78 205 207 O
dosing 79 85 208 214 O

History 0 7 215 222 O
or 8 10 223 225 O
evidence 11 19 226 234 O
of 20 22 235 237 O
retinal 23 30 238 245 O
pathology 31 40 246 255 O
on 41 43 256 258 O
ophthalmologic 44 58 259 273 O
examination 59 70 274 285 O
that 71 75 286 290 O
is 76 78 291 293 O
considered 79 89 294 304 O
a 90 91 305 306 O
risk 92 96 307 311 O
factor 97 103 312 318 O
for 104 107 319 322 O
neurosensory 108 120 323 335 B-chronic_disease
retinal 121 128 336 343 I-chronic_disease
detachment 129 139 344 354 I-chronic_disease
/ 139 140 354 355 O
central 140 147 355 362 B-chronic_disease
serous 148 154 363 369 I-chronic_disease
chorioretinopathy 155 172 370 387 I-chronic_disease
( 173 174 388 389 I-chronic_disease
CSCR 174 178 389 393 I-chronic_disease
) 178 179 393 394 I-chronic_disease
, 179 180 394 395 O
retinal 181 188 396 403 B-chronic_disease
vein 189 193 404 408 I-chronic_disease
occlusion 194 203 409 418 I-chronic_disease
( 204 205 419 420 I-chronic_disease
RVO 205 208 420 423 I-chronic_disease
) 208 209 423 424 I-chronic_disease
, 209 210 424 425 O
or 211 213 426 428 O
neovascular 214 225 429 440 B-chronic_disease
macular 226 233 441 448 I-chronic_disease
degeneration 234 246 449 461 I-chronic_disease

Ineligible 0 10 462 472 O
for 11 14 473 476 O
allogeneic 15 25 477 487 B-treatment
stem 26 30 488 492 I-treatment
cell 31 35 493 497 I-treatment
transplant 36 46 498 508 I-treatment

Known 0 5 509 514 O
active 6 12 515 521 O
central 13 20 522 529 O
nervous 21 28 530 537 O
system 29 35 538 544 O
( 36 37 545 546 O
CNS 37 40 546 549 O
) 40 41 549 550 O
involvement 42 53 551 562 O
with 54 58 563 567 O
AML 59 62 568 571 B-cancer
at 63 65 572 574 O
study 66 71 575 580 O
entry 72 77 581 586 O

LVEF 0 4 587 591 B-clinical_variable
below 5 10 592 597 O
institutional 11 24 598 611 O
LLN 25 28 612 615 B-clinical_variable
or 29 31 616 618 O
below 32 37 619 624 O
50 38 40 625 627 B-upper_bound
% 40 41 627 628 I-upper_bound
, 41 42 628 629 O
whichever 43 52 630 639 O
is 53 55 640 642 O
lower 56 61 643 648 O

Left 0 4 649 653 B-clinical_variable
ventricular 5 16 654 665 I-clinical_variable
ejection 17 25 666 674 I-clinical_variable
fraction 26 34 675 683 I-clinical_variable
( 35 36 684 685 I-clinical_variable
LVEF 36 40 685 689 I-clinical_variable
) 40 41 689 690 I-clinical_variable
below 42 47 691 696 O
institutional 48 61 697 710 O
lower 62 67 711 716 B-clinical_variable
limit 68 73 717 722 I-clinical_variable
of 74 76 723 725 I-clinical_variable
normal 77 83 726 732 I-clinical_variable
( 84 85 733 734 I-clinical_variable
LLN 85 88 734 737 I-clinical_variable
) 88 89 737 738 I-clinical_variable
or 90 92 739 741 O
below 93 98 742 747 O
50 99 101 748 750 B-upper_bound
% 101 102 750 751 I-upper_bound
, 102 103 751 752 O
whichever 104 113 753 762 O
is 114 116 763 765 O
lower 117 122 766 771 O

Life 0 4 772 776 B-clinical_variable
expectancy 5 15 777 787 I-clinical_variable
of 16 18 788 790 O
at 19 21 791 793 O
least 22 27 794 799 O
12 28 30 800 802 B-lower_bound
weeks 31 36 803 808 I-lower_bound

Not 0 3 809 812 O
eligible 4 12 813 821 O
for 13 16 822 825 O
cytotoxic 17 26 826 835 B-treatment
therapies 27 36 836 845 I-treatment

Patients 0 8 846 854 O
with 9 13 855 859 O
acute 14 19 860 865 B-cancer
promyelocytic 20 33 866 879 I-cancer
leukemia 34 42 880 888 I-cancer
( 43 44 889 890 O
French 44 50 890 896 O
- 50 51 896 897 O
American 51 59 897 905 O
- 59 60 905 906 O
British 60 67 906 913 O
[ 68 69 914 915 O
FAB 69 72 915 918 O
] 72 73 918 919 O
class 74 79 920 925 O
M3 80 82 926 928 O
AML 83 86 929 932 O
) 86 87 932 933 O

Positive 0 8 934 942 O
for 9 12 943 946 O
hepatitis 13 22 947 956 B-chronic_disease
C 23 24 957 958 I-chronic_disease
virus 25 30 959 964 I-chronic_disease
( 31 32 965 966 I-chronic_disease
HCV 32 35 966 969 I-chronic_disease
) 35 36 969 970 I-chronic_disease
, 36 37 970 971 O
hepatitis 38 47 972 981 B-chronic_disease
B 48 49 982 983 I-chronic_disease
surface 50 57 984 991 I-chronic_disease
antigen 58 65 992 999 I-chronic_disease
( 66 67 1000 1001 I-chronic_disease
HBsAg 67 72 1001 1006 I-chronic_disease
) 72 73 1006 1007 I-chronic_disease
and 74 77 1008 1011 O
known 78 83 1012 1017 O
history 84 91 1018 1025 O
of 92 94 1026 1028 O
HIV 95 98 1029 1032 B-chronic_disease
, 98 99 1032 1033 O
malignancy 100 110 1034 1044 B-cancer
, 110 111 1044 1045 O
active 112 118 1046 1052 B-chronic_disease
infection 119 128 1053 1062 I-chronic_disease
and 129 132 1063 1066 O
cardiovascular 133 147 1067 1081 B-chronic_disease
diseases 148 156 1082 1090 I-chronic_disease
( 157 158 1091 1092 I-chronic_disease
CVs 158 161 1092 1095 I-chronic_disease
) 161 162 1095 1096 I-chronic_disease

Prior 0 5 1097 1102 O
exposure 6 14 1103 1111 O
to 15 17 1112 1114 O
Bcl-2 18 23 1115 1120 B-treatment
inhibitors 24 34 1121 1131 I-treatment
, 34 35 1131 1132 O
murine 36 42 1133 1139 B-treatment
double 43 49 1140 1146 I-treatment
minute 50 56 1147 1153 I-treatment
2 57 58 1154 1155 I-treatment
( 59 60 1156 1157 I-treatment
MDM2 60 64 1157 1161 I-treatment
) 64 65 1161 1162 I-treatment
antagonists 66 77 1163 1174 I-treatment
or 78 80 1175 1177 O
prior 81 86 1178 1183 O
exposure 87 95 1184 1192 O
to 96 98 1193 1195 O
experimental 99 111 1196 1208 B-treatment
treatment 112 121 1209 1218 I-treatment
targeting 122 131 1219 1228 I-treatment
Raf 132 135 1229 1232 I-treatment
, 135 136 1232 1233 O
mitogen 137 144 1234 1241 B-treatment
- 144 145 1241 1242 I-treatment
activated 145 154 1242 1251 I-treatment
protein 155 162 1252 1259 I-treatment
kinase 163 169 1260 1266 I-treatment
( 170 171 1267 1268 I-treatment
MEK 171 174 1268 1271 I-treatment
) 174 175 1271 1272 I-treatment
, 175 176 1272 1273 O
or 177 179 1274 1276 O
the 180 183 1277 1280 O
mitogen 184 191 1281 1288 B-treatment
- 191 192 1288 1289 I-treatment
activated 192 201 1289 1298 I-treatment
protein 202 209 1299 1306 I-treatment
kinase 210 216 1307 1313 I-treatment
( 217 218 1314 1315 I-treatment
MAPK 218 222 1315 1319 I-treatment
) 222 223 1319 1320 I-treatment
RAS 224 227 1321 1324 I-treatment
/ 227 228 1324 1325 I-treatment
RAF 228 231 1325 1328 I-treatment
/ 231 232 1328 1329 I-treatment
MEK 232 235 1329 1332 I-treatment
/ 235 236 1332 1333 I-treatment
ERK 236 239 1333 1336 I-treatment
MAPK 240 244 1337 1341 I-treatment
pathway 245 252 1342 1349 I-treatment

Received 0 8 1350 1358 O
strong 9 15 1359 1365 O
cytochrome 16 26 1366 1376 B-treatment
( 27 28 1377 1378 I-treatment
CYP 28 31 1378 1381 I-treatment
) 31 32 1381 1382 I-treatment
3A 33 35 1383 1385 I-treatment
inhibitors 36 46 1386 1396 I-treatment
, 46 47 1396 1397 O
moderate 48 56 1398 1406 O
CYP3A 57 62 1407 1412 B-treatment
inhibitors 63 73 1413 1423 I-treatment
, 73 74 1423 1424 O
strong 75 81 1425 1431 B-treatment
CYP3A 82 87 1432 1437 I-treatment
inducers 88 96 1438 1446 I-treatment
and 97 100 1447 1450 O
moderate 101 109 1451 1459 B-treatment
CYP3A 110 115 1460 1465 I-treatment
inducers 116 124 1466 1474 I-treatment
within 125 131 1475 1481 O
7 132 133 1482 1483 B-upper_bound
days 134 138 1484 1488 I-upper_bound
prior 139 144 1489 1494 I-upper_bound
to 145 147 1495 1497 O
initiation 148 158 1498 1508 O
of 159 161 1509 1511 O
study 162 167 1512 1517 O
treatment 168 177 1518 1527 O

Received 0 8 1528 1536 O
the 9 12 1537 1540 O
following 13 22 1541 1550 O
within 23 29 1551 1557 O
7 30 31 1558 1559 B-upper_bound
days 32 36 1560 1564 I-upper_bound
prior 37 42 1565 1570 I-upper_bound
to 43 45 1571 1573 O
the 46 49 1574 1577 O
initiation 50 60 1578 1588 O
of 61 63 1589 1591 O
study 64 69 1592 1597 O
treatment 70 79 1598 1607 O

